Reduced periinfarction mortality as a result of long-term therapy with captopril but not hydralazine or propranolol in spontaneously hypertensive rats

Journal of Cardiovascular Pharmacology

Volumn 32, Issue 6, 1998, Pages 884-895

  Nguyen, Tan ^a,b   El Salibi, Elias ^a   Rouleau, Jean L ^a,b  

^a MONTREAL HEART INSTITUTE   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Captopril; Cardiac fibrosis; Concentric myocardial hypertrophy; Mortality periinfarction; SHR; Ventricular arrhythmias

Indexed keywords

CAPTOPRIL; HYDRALAZINE; PROPRANOLOL;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART VENTRICLE ARRHYTHMIA; HYPERTENSION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; TREATMENT OUTCOME;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CAPTOPRIL; COLLAGEN; ELECTRIC STIMULATION; HEART RATE; HYDRALAZINE; HYPERTENSION; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MYOCARDIAL INFARCTION; PROPRANOLOL; RATS; RATS, INBRED SHR; SURVIVAL ANALYSIS;

EID: 0031646535     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199812000-00004     Document Type: Article

References (58)

1. Kannel WB, Castelli WP, McNamara PM, McKee PA, Feinleib M. Role of blood pressure in the development of congestive heart failure: the Framingham Study. N Engl J Med 1972;287:781-7.
2. Post WS, Larson MG, Levy D. Impact of left ventricular structure on the incidence of hypertension: the Framingham heart study. Circulation 1994;90:179-85.
3. Rouleau L, Talajic M, Sussex B, et al. Myocardial infarction patients in the 1990s: their risk factors, stratification and survival in Canada: the Canadian Assessment of Myocardial Infarction (CAMI) study. J Am Coll Cardiol 1996;27:1119-27.
4. Bélichard P, Pruneau D, Brown NL, Salzmann JL, Rouet R. Hypertrophie myocardique hypertensive et troubles du rythme: deux origines probables. Arch Mal Coeur Vaiss 1989;82:1303-8.
5. Hinglais N, Heudes D, Nicoletti A, et al. Co-localization of myocardial fibrosis and inflammatory cells in rats. Lab Invest 1994;70:286-94.
6. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation 1991;83:1849-65.
7. Conrad CH, Brooks WW, Hayes JA, Sen S, Robinson KG, Bing OHL. Myocardial fibrosis and stiffness with hypertrophy and heart failure in the spontaneous hypertensive rat. Circulation 1995;91:161-70.
8. Brilla CG, Weber KT. Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. Cardiovasc Res 1992;26:671-7.
9. Salzmann JL, Michel JB, Bruneval P, et al. Automated image analysis of myocardial collagen pattern in pressure and volume overload in rat cardiac hypertrophy. Anal Quant Cytol Histol 1986;8:326-32.
10. Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 1990;67:1355-64.
11. Levy D, Anderson KM, Savage DD, Balkus SA, Kannel WB, Castelli WP. Risk of ventricular arrhythmias in left ventricular hypertrophy: the Framingham Heart Study. Am J Cardiol 1987;60:560-5.
12. McLenachan JM, Henderson E, Morris KI, Dargie HJ. Ventricular arrhythmias in patients with hypertensive left ventricular hypertrophy. N Engl J Med 1987;317:787-92.
13. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essentiel hypertension. Ann Intern Med 1991;114:345-52.
14. Dahlöf B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients: a meta-analysis of 109 treatment studies. Am J Hypertens 1992;5:95-110.
15. 1 angiotensin II inhibition. J Hypertens 1995;13:1808-12.
16. Pahor M, Bernabei R, Sgadari A, et al. Enalapril prevents cardiac fibrosis and arrhythmias in hypertensive rats. Hypertension 1991;18:148-57.
17. Kohya T, Yokoshiki H, Tohse N, et al. Regression of left ventricular hypertrophy prevents ischemia-induced lethal arrhythmias. Circ Res 1995;76:892-9.
18. Opitz CF, Mitchell GF, Pfeffer MA, Pfeffer J. Arrhythmias and death after coronary artery occlusion in the rat. Circulation 1995;92:253-61.
19. Curtis MJ, MacLeod BA, Walker MJ. Models for the study of arrhythmias in myocardial ischaemia and infarction: the use of the rat. J Mol Cell Cardiol 1987;19:399-419.
20. Johnston KM, MacLeod BA, Walker MJ. Responses to ligation of a coronary artery in conscious rats and the actions of antiarrhythmics. Can J Physiol Pharmacol 1983;61:1340-53.
21. Fishbein MC, Lei LQ, Rubin SA. Long-term propranolol administration alters myocyte and ventricular geometry in rat hearts with and without infarction. Circulation 1988;78:369-75.
22. Messerli FH, Oren S, Grossman E. Left ventricular hypertrophy and antihypertensive therapy. Drugs 1988;35(suppl V):27-33.
23. Bruckschlegel G, Holmer SR, Jandeleit K, et al. Blockade of the renin-angiotensin system in cardiac pressure-overload hypertrophy in rats. Hypertension 1995;25:250-9.
24. Pfeffer MA, Pfeffer JM. Pharmacologic regression of cardiac hypertrophy in experimental hypertension. J Cardiovasc Pharmacol 1984;6:5865-9.
25. Sen S, Bumpus FM. Collagen synthesis in development and reversal of cardiac hypertrophy in spontaneously hypertensive rats. Am J Cardiol 1979;44:954-8.
26. Mitchell GF, Pfeffer MA, Finn PV, Pfeffer JM. Equipotent antihypertensive agents variously affect pulsatile hemodynamics and regression of cardiac hypertrophy in spontaneously hypertensive rats. Circulation 1996;94:2923-9.
27. Pfeffer JM, Pfeffer MA, Fletcher PJ, Fishbein MC, Braunwald E. Favorable effects of therapy on cardiac performance in spontaneously hypertensive rats. Am J Physiol 1982;242:H776-84.
28. Pfeffer JM, Pfeffer MA, Mirsky I, Braunwald E. Regression of left ventricular hypertrophy and prevention of ventricular dysfunction by captopril in the spontaneously hypertensive rats Proc Natl Acad Sci USA 1982;79:3310-4.
29. Weber KT, Sun Y, Guarda E. Structural remodeling in hypertensive heart disease and the role of hormones. Hypertension 1994;23:869-77.
30. Friedrich SP, Lorell BH, Rousseau MF, et al. Increased angiotensin-converting enzyme inhibition improves diastolic function in patients with left ventricular hypertrophy due to aortic stenosis. Circulation 1994;90:2761-71.
31. Sen S, Tarazi RC, Bumpus M. Effect of converting enzyme inhibitor (SQ 14,225) on myocardial hypertrophy in spontaneously hypertensive rats. Hypertension 1980;2:169-76.
32. Bélichard P, Savard P, Cardinal R, et al. Markedly different effects on ventricular remodeling result in a decrease in inducibility of ventricular arrhythmias. J Am Coll Cardiol 1994;23:505-13.
33. Anderson PG, Bishop SP, Digerness SB. Vascular remodeling and improvement of coronary reserve after hydralazine treatment in spontaneously hypertensive rats. Circ Res 1989;64:1127-36.
34. Pfeffer JM, Pfeffer MA, Frohlich ED. Validity of an indirect tailcuff method for determining systolic arterial pressure in unanesthetized normotensive and spontaneously hypertensive rats. J Lab Clin Med 1971;78:957-62.
35. Buxton AE, Waxman HL, Marchlinski FE, Untereker WJ, Waspe LE, Josephson ME. Role of triple extrastimuli during electrophysiologic study of patients with documented sustained ventricular tachyarrhythmias. Circulation 1984;69:532-40.
36. Pfeffer MA, Pfeffer JM, Fishbein MC, et al. Myocardial infarct size and ventricular function in rats. Circ Res 1974;44:503-12.
37. Junqueira LCU, Bignolas G, Brentani R. Picrosirius staining plus polarizing microscopy: a specific method for collagen detection in tissue sections. Histochem J 1979;11:445-7.
38. Junqueira LCU, Montes GS, Sanchez EM. The influence of tissue thickness on the study of collagen by the picrosirius-polarization method. Histochemistry 1982;74:153-6.
39. Marijianowski M, Teeling P, Mann J, Becker A. Dilated cardiomyopathy is associated with an increase in the type I/type III collagen ratio: a quantitative assessment. J Am Coll Cardiol 1995;25:1263-72.
40. Dellsperger KC, Clothier JL, Hartnett JA, Haun LM, Marcus ML. Acceleration of the wavefront of myocardial necrosis by chronic hypertension and left ventricular hypertrophy in dogs. Circ Res 1988;63:87-96.
41. Wit AL, Janse MJ. Ventricular arrhythmias in the acute phase of myocardial ischemia and infarction. In: Wit AL, Janse MJ, eds. The ventricular arrhythmias of ischemia and infarction: electrophysiological mechanisms. Mount Kisko, NY: Futura Publishing, 1993:174-260.
42. Kabell G, Scherlag BJ, Hope RR, Lazzara R. Regional myocardial blood flow and ventricular arrhythmias following one-stage and two-stage coronary artery occlusion in anesthetized dogs. Am Heart J 1982;104:537-44.
43. Kaplinski E, Ogawa S, Balke CW, Dreifus LS. Two periods of early ventricular arrhythmia in the canine acute myocardial infarction model. Circulation 1979;60:397-403.
44. Thollon C, Kreher P, Charlon V, Rossi A. Hypertrophy induced alteration of action potential and effects of the inhibition of angiotensin converting enzyme by perindopril in infarcted rat hearts. Cardiovasc Res 1989;23:224-30.
45. Freslon JL, Giudicelli JF. Compared myocardial and vascular effects of captopril and dihydralazine during hypertension development in spontaneously hypertensive rats. Br J Pharmacol 1983;80:533-13.
46. Muirhead EE, Prewitt RL, Brooks B, Brosius WL. Antihypertensive action of the orally active converting enzyme inhibitor (SQ14,225) in spontaneously hypertensive rats. Circ Res 1978;43:I-53-9.
47. Koike H, Ito K, Miyamoto M, Nishino H. Effects of long-term blockade of angiotensin converting enzyme with captopril (SQ14,225) on hemodynamics and circulating blood volume in SHR. Hypertension 1980;2:299-303.
48. Heagerty AM, Bund SJ, Aalkjaer C. Effects of drug treatment on human resistance arteriole morphology in essential hypertension: direct evidence for structural remodelling of resistance vessels. Lancet 1988;2:1209-12.
49. Canby CA, Tomanek RJ. Role of lowering arterial pressure on maximal coronary flow with and without regression of cardiac hypertrophy. Am J Physiol 1989;257:H-1110-8.
50. Schiffrin EL, Deng LY, Larochelle P. Effects of a β-blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension. Hypertension 1994;23:83-91.
51. Antony I, Nitenberg A, Foult JM, Aptecar E. Coronary vasodilator reserve in untreated and treated hypertensive patients with and without left ventricular hypertrophy. J Am Coll Cardiol 1993;22:514-20.
52. Clozel M. Mechanism of action of angiotensin converting enzyme inhibitors on endothelial function in hypertension. Hypertension 1991;18(suppl II):II-37-42.
53. Strauer BE. Regression of myocardial and coronary vascular hypertrophy in hypertensive heart disease. J Cardiovasc Pharmacol 1988;12(suppl 4):S45-54.
54. Michel JB, Levy BI. Vascular effects of ACE inhibition by perindopril. Drugs 1990;39(suppl 1):39-42.
55. Hochmann JS, Choo H. Limitation of myocardial infarct expansion by reperfusion independent of myocardial salvage. Circulation 1987;75:299-306.
56. Wit AL, Janse MJ. Delayed ventricular arrhythmias in the subacute phase of myocardial infarction. In: Wit AL, Janse MJ, eds. The ventricular arrhythmias of ischemia and infarction: electrophysiological mechanisms. Mount Kisko, NY: Futura Publishing, 1993: 267-337.
57. Mukherjee D, Sen S. Collagen phenotypes during development and regression of myocardial hypertrophy in spontaneously hypertensive rats. Circ Res 1990;67:1474-80.
58. Weber KT, Sun Y, Guarda E. Structural remodeling in hypertensive heart disease and the role of hormones. Hypertension 1994;23(pt 2):869-77.